MeiraGTx Holdings (MGTX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $2.52
- Estimate
- -$0.42
- Surprise
- +697.3%
- Revenue (period 2026-06-30)
- $321.4M
- Score at report (before → after)
- 5.3 → 5.7/10
Revenue source: xbrl.
How the report landed
MeiraGTx Holdings (MGTX) beat the -$0.42 estimate with diluted EPS of $2.52 — a large 697.3% upside surprise. TrendMatrix's engine moved from Sell (5.3/10) to Hold at 5.7/10 after the report.
Coverage in the report window
- RBC Capital Maintains Outperform on MeiraGTx Holdings, Raises Price Target to $27 — benzinga, 2026-08-14
- MeiraGTx Hldgs Q2 EPS $1.71 Beats $(0.46) Estimate, Sales $321.434M Beat $12.476M Estimate — benzinga, 2026-08-13
- MeiraGTx Hldgs Q2 Sales $321.434M Beat $12.476M Estimate — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates MGTX Hold at 7.0/10.
2 of the last 4 quarters beat the estimate; this quarter's +697.3% surprise compares with a +193.5% four-quarter average. Next scheduled report: 2026-11-12.
What supports the rating
- High-quality business
- Attractive valuation
What argues against it
- Consecutive earnings misses (2)
- Overbought (RSI 77)
- News modifier -1: STRONG_BUY_WAIT → HOLD_IF_HOLDING
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $14.34
- Price target
- $25.60
- Stop
- $13.34
- Upside to target
- +78.5%
- Reward-to-risk
- 5.2:1
Risk check: RSI 77 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
MGTX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.38B
- P/E (fwd)
- -10.3
- P/E (ttm)
- 16.7
- 52-week range
- $6.62–$15.35
- Off 52-week high
- 6.6%
- RSI (14)
- 77
- Volume vs avg
- 1.11×
- Score today
- 7.0/10